Form 8-K - Current report:
SEC Accession No. 0001193125-25-027349
Filing Date
2025-02-14
Accepted
2025-02-14 16:59:27
Documents
13
Period of Report
2025-02-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.03: Bankruptcy or Receivership
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K d896578d8k.htm   iXBRL 8-K 32620
  Complete submission text file 0001193125-25-027349.txt   161633

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA omga-20250210.xsd EX-101.SCH 2868
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE omga-20250210_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE omga-20250210_pre.xml EX-101.PRE 11719
15 EXTRACTED XBRL INSTANCE DOCUMENT d896578d8k_htm.xml XML 3767
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 25630496
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)